Abstracts Archive - Page 195 of 2425 - ACR Meeting Abstracts

Abstract Number: 0444 • ACR Convergence 2023
Safety, Tolerability, and Pharmacokinetics of a Novel Synthetic Disease Modifying Antirheumatic Drug, TCK-276, After Single Ascending Dose in Healthy Subjects and Multiple Ascending Doses in Patients with Rheumatoid Arthritis
Chie Watai¹, Kazuoki Tsuruda², Yoshinori Tsumura¹ and Daisuke Tasaki¹, ¹Teijin Pharma Limited, Chiyoda City Tokyo, Japan, ²Teijin America, Inc., Sausalito, CA
Background/Purpose: TCK-276 is a highly potent, orally active, and selective cyclin dependent kinase 4/6 (CDK4/6) inhibitor that is in development as a novel synthetic disease…
Abstract Number: 0368 • ACR Convergence 2023
Surveying Psychological Resilience and Pain in a Cross-Section of JIA Patients
Daniella Schocken and Tracy Ting, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Pain trajectories vary in JIA, with some patients developing chronic pain over the course of their illness. Adaptation and recovery under stressful or traumatic…
Abstract Number: 0438 • ACR Convergence 2023
Association Between Methotrexate Use and Lymphoma in Rheumatoid Arthritis: A Systematic Literature Review
Swetha Ann Alexander¹, Gordon Starkebaum², Diana Louden², Grant Hughes² and Namrata Singh³, ¹University of Utah Health, Salt Lake City, UT, ²University of Washington, Seattle, WA, ³University of Washington, Bellevue, WA
Background/Purpose: Rheumatoid Arthritis (RA) patients have an increased risk of developing lymphoma compared to the general population. This increased risk is believed to be linked…
Abstract Number: 0447 • ACR Convergence 2023
Glucocorticoid Use in Rheumatoid Arthritis Patients Initiating Biological or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs (b/tsDMARDs) in Real Life: Data from BIOBADASER
Lucia Otero-Valera¹, Jose María Alvaro-Gracias², Jerusalem Calvo³, Cristina Campos⁴, Alicia Garcia Dorta⁵, Fernando Sánchez-Alonso⁶ and Isabel Castrejon⁷, ¹Spanish Society of Rheumatology, Madrid, Spain, ²Hospital General Universitario Gregorio Marañon, Madrid, Spain, ³Reina Sofia University Hospital, Córdoba, Spain, ⁴Rheumatology Unit, Hospital General Universitario de Valencia, Valencia, Spain, ⁵Rheumatology Unit, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁶Fundación Española de Reumatología, Madrid, Spain, ⁷Hospital Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: Glucocorticoids are frequently used as bridging therapy for rheumatoid arthritis (RA) patients starting conventional synthetic DMARDs. Both EULAR and ACR guidelines (1,2), recommend to…
Abstract Number: 0450 • ACR Convergence 2023
Baricitinib versus TNF-inhibitors in Patients with Active Rheumatoid Arthritis After Failure of CsDMARDs: A Pragmatic, Multicenter, Real-Life Study in a Treat-to-Target Setting
Martinus Van de Laar¹, Martijn Oude Voshaar¹, Peter ten Klooster¹, Danyta Tedjo² and celine van de laar³, ¹University of Twente, Hengelo (OV), Netherlands, ²TiH @ University of Twente, Hengelo (OV), Netherlands, ³Erasmus School of Health Policy and Management, Erasmus University, Rotterdam, Netherlands
Background/Purpose: The EULAR guidelines for Rheumatoid Arthritis (RA) patients advise to use a strategy aiming at a predefined target of disease activity (T2T). If this…
Abstract Number: 0454 • ACR Convergence 2023
Rheumatoid Arthritis Disease Activity Indices Assess More Than Inflammation: 29%-36% of Patients with Moderate or High DAS28–ESR or CDAI Have 0 or 1 Swollen Joints, but Positive Screens on MDHAQ FAST4 (fibromyalgia Assessment Screening Tool) And/or MDS2 (MDHAQ Depression Screen) Indices
Theodore Pincus¹, Nicholas Rodwell² and Rahel Hunter¹, ¹Rush University Medical Center, Chicago, IL, ²University of New South Wales, Sydney, Australia
Background/Purpose: Rheumatoid arthritis (RA) therapy is recommended to be intensified according to treat-to-target if DAS28 (disease activity score 28) or CDAI (clinical disease activity index)…
Abstract Number: 0398 • ACR Convergence 2023
Identification of Disease Activity-related miRNAs Through Artificial Neural Network Analysis in Rheumatoid Arthritis
Milena Rodriguez Alvarez¹, Lissette Delgado-Cruzata², Anna Tryfonos¹, Nickolas Almodovar², Toni-Ann Bravo² and Naureen Kabani¹, ¹SUNY Downstate Health Sciences University, Brooklyn, NY, ²The City University of New York, John Jay College, New York, NY
Background/Purpose: Rheumatoid Arthritis (RA) is the result of the complex interplay between genetic, epigenetic, and environmental factors leading to immune dysregulation, synovial membrane inflammation, and…
Abstract Number: 0411 • ACR Convergence 2023
The Impact of Patient-reported Outcomes on Boolean 2.0 Remission Criteria in Rheumatoid Arthritis Patients in Real Clinical Practice -a Multicenter Observational Study: T-FLAG Study-
Mochihito Suzuki¹, yoshifumi Ohashi¹, Yasumori Sobue², Ryo Sato¹, Masataka Maeda¹, Hironobu Kosugiyama¹, yusuke Ohno¹, kenya terabe³, Shuji Asai¹ and Shiro Imagama¹, ¹Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan, ³Nagoya University, Nagoya, Japan
Background/Purpose: The Boolean remission criteria proposed by the The American College of Rheumatology (ACR) and the European College of Rheumatology (EULAR) in 2011 are widely…
Abstract Number: 0431 • ACR Convergence 2023
Senescence and Cell Exhaustion in CD4+ and CD8+ Lymphocytes in Rheumatoid Arthritis Patients in Remission Without Treatment
Rodolfo Jiménez-Soto¹, Luis llorente², Guadalupe Lima¹, Luisa Alanis Saenz¹, Amairani Gomez Rodriguez¹, Hilda Marin Lopez¹, Erik Cimé-Aké¹ and Juan Jakez-Ocampo¹, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Departamento de Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: T cells are important among the several risk factors and immunological markers implicated in rheumatoid arthritis (RA). The goal of this study was to…
Abstract Number: 0400 • ACR Convergence 2023
Thresholds of Presenteeism Measurement Instruments for Unacceptable Work Participation and Future Adverse Work Outcomes in Rheumatoid Arthritis
Dafne Capelusnik¹, Sofia Ramiro², Elena Nikiphorou³, Walter P. Maksymowych⁴, Marina Nighat Magrey⁵, Helena Marzo-Ortega⁶ and Annelies Boonen⁷, ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³King's College London, London, United Kingdom, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Case Western Reserve University, University Hospitals, Cleveland, OH, ⁶NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁷Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands
Background/Purpose: Presenteeism is associated with lower work satisfaction and increased risk of future sick leave in rheumatic diseases. It is generally measured on a continuous…
Abstract Number: 0434 • ACR Convergence 2023
Effects of B/tsDMARDs on Non-inflammatory Pain in Patients with Rheumatoid Arthritis -ANSWER Longitudinal Cohort Study-
Mai Yamashita¹, Takaichi Okano¹, Iku Shirasugi¹, Hirotaka Yamada¹, Keisuke Nishimura¹, Sho Sendo¹, Yo Ueda¹, Toshihisa Maeda², Shinya Hayashi², Wataru Yamamoto³, Akira Onishi⁴, Kosaku Murakami⁵, Hideyuki Shiba⁶, Kenichiro Hata⁶, Kohei Tsujimoto⁷, Kosuke Ebina⁸, Yonsu Son⁹, Naofumi Yoshida⁹, Ryota Hara¹⁰, Ryu Watanabe¹¹, Motomu Hashimoto¹¹, Ryosuke Kuroda² and Jun Saegusa¹, ¹Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ³Department of Health Information Management, Kurashiki Sweet Hospital, Kurashiki, Japan, ⁴Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁶Department of Internal Medicine (Ⅳ), Osaka Medical and Pharmaceutical University, Takatsuki, Japan, ⁷Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Toyonaka, Osaka, Japan, ⁸Department of Musculoskeletal Regenerative Medicine, Osaka University, Graduate School of Medicine, Toyonaka,Osaka, Japan, ⁹First Department of Internal Medicine, Kansai Medical University, Osaka, Hirakata, Japan, ¹⁰Department of Orthopaedic Surgery, Nara Medical University, Nara, Japan, ¹¹Department of Clinical Immunology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
Background/Purpose: Non-inflammatory pain (NIP) is one of the remaining issues in rheumatoid arthritis (RA), and some previous studies suggest that 10-20% of patients with RA…
Abstract Number: 0414 • ACR Convergence 2023
Association of a Treat-to-Target Management Approach with Physician and Patient Reported Outcomes Among Real – World Patients with Rheumatoid Arthritis Receiving Advanced Therapy in Europe
Douglas White¹, Aditi Kadakia², Oliver Howell³, Sander Strengholt⁴, Emily Goddard³, Sophie Barlow³ and Tsutomu Takeuchi⁵, ¹Waikato Clinical School, University of Auckland, Hamilton, New Zealand, ²AbbVie, Inc., North Chicago, IL, ³Adelphi Real World, Bollington, United Kingdom, ⁴AbbVie B.V., Mijdrecht, Utrecht, Netherlands, ⁵Keio University School of Medicine and Saitama Medical University, Tokyo, Japan
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease affecting the joints, causing swelling, stiffness, and pain that impact a patient's quality of life. EULAR treatment…
Abstract Number: 0453 • ACR Convergence 2023
Risk of Lung Cancer in Veterans with Rheumatoid Arthritis in Relation to Use of Conventional versus Biologic or Targeted Synthetic DMARDs
Namrata Singh¹, Alexander Peterson², Aaron Baraff², K Wysham³, Bryant England⁴, Joshua Baker⁵, Nicholas Smith², Ted R Mikuls⁶ and Noel Weiss⁷, ¹University of Washington, Bellevue, WA, ²VA Puget Sound Seattle, Seattle, WA, ³VA Puget Sound/University of Washington, Seattle, WA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁷University of Washington, Seattle, WA
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of lung cancer compared to the general population. While smoking is a shared risk factor,…
Abstract Number: 0429 • ACR Convergence 2023
Direct and Indirect Effects of Upadacitinib or Adalimumab on Pain in Rheumatoid Arthritis: Results from a Randomized Phase 3 Study
Peter C. Taylor¹, David Walsh², Tsutomu Takeuchi³, Bruno Fautrel⁴, Janet Pope⁵, Andrew Garrison⁶, Yanna Song⁶, Sara K. Penn⁶, Ralph Lippe⁷, Diane Caballero⁸ and Arthur Kavanaugh⁹, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²University of Nottingham, Nottingham, United Kingdom, ³Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ⁴Sorbonne Université APHP, Paris, France, ⁵University of Western Ontario, London, ON, Canada, ⁶AbbVie, Inc., North Chicago, IL, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁸AbbVie, Inc., Chicago, IL, ⁹University of California San Diego, School of Medicine, Riverside, CA
Background/Purpose: Rapid and sustained pain control is an important goal for patients (pts) with rheumatoid arthritis (RA). Control of inflammation in RA does not always…
Abstract Number: 0353 • ACR Convergence 2023
Validation of Claims-based Algorithms for Newly Diagnosed Juvenile Idiopathic Arthritis Using Machine Learning Methods
Patricia Hoffman¹, Lauren Parlett², Daniel Beachler², Daniel Reiff³, Sarah McGuire¹, Sonia Pothraj¹, Lakshmi Moorthy¹, Cynthia Salvant⁴, Dawn Koffman⁵, Sanika Rege⁵, Cecilia Huang⁵, Matthew Iozzio⁵, Kevin Schott², Kevin Haynes⁶, Amy Davidow⁷, Stephen Crystal⁸, Tobias Gerhard⁵, Brian Strom⁹, Carlos Rose¹⁰ and Daniel Horton⁴, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Carelon, Wilmington, DE, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁵Rutgers Center for Pharmacoepidemiology and Treatment Science, New Brunswick, NJ, ⁶Janssen Pharmaceuticals, Raritan, NJ, ⁷New York University, New York, NY, ⁸Rutgers University, New Brunswick, NJ, ⁹Rutgers, State University of New Jersey, New Brunswick, NJ, ¹⁰Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Administrative claims databases represent important settings for studying large populations with juvenile idiopathic arthritis (JIA), but prior efforts to validate diagnostic algorithms for JIA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].